Keyphrases
Neoadjuvant
74%
Overall Survival
62%
Tumor Microenvironment
61%
Metastatic Pancreatic Ductal Adenocarcinoma
59%
Irinotecan
54%
Pancreatic Ductal Adenocarcinoma
52%
Phase II Study
45%
Metastatic Colorectal Cancer (mCRC)
45%
Guadecitabine
45%
Phase I Trial
45%
Nivolumab
45%
Neoadjuvant Therapy
36%
Cellular Immune Response
35%
T Cells
34%
CD137
34%
Allogeneic
34%
Effector T Cells
34%
Vaccine Response
33%
Lymphoid Aggregates
32%
DNA Vaccine
32%
Therapeutic Vaccine
30%
Dose Level
30%
Viral Replication
27%
Programmed Death-ligand 1 (PD-L1)
26%
Pancreatic Cancer
26%
Plasmid
26%
Macaque
26%
Pancreatic Tumor
22%
Change Analysis
22%
Anti-PD-1 Therapy
22%
TAS-102
22%
Clinical Trials
22%
Memory Subsets
22%
Epigenetic Modulators
22%
Advanced Colorectal Cancer
22%
Immune Response
22%
Disease-free Survival
22%
Pancreatic Adenocarcinoma
22%
Multi-omics Analysis
22%
Interleukin-15 (IL-15)
22%
Setpoint Following
22%
Viral Load
22%
Microsatellite Stable
22%
Ipilimumab
22%
Trametinib
22%
Pembrolizumab
22%
Intravenous Ascorbate
22%
CCL27
22%
CCL28
22%
Antiretroviral Therapy
22%
Immunology and Microbiology
Vaccine Efficacy
100%
Plasmid
68%
Simian Immunodeficiency Virus
59%
Immune Response
54%
T Cell
49%
DNA Vaccine
48%
Rhesus Monkey
45%
Interleukin 15
45%
Overall Survival
44%
Nivolumab
42%
Adoptive Immunity
41%
CD8
40%
Arm
36%
Viral Load
36%
Immunotherapy
36%
T-Helper Cell
33%
Cytotoxic T-Cell
33%
Viral Replication
32%
Human Immunodeficiency Virus
29%
Vaccination Policy
27%
Macaca
26%
Vaccine Adjuvant
25%
Monospecific Antibody
22%
Multi-Omics
22%
Interleukin 12
22%
CCL28
22%
Cutaneous T Cell Attracting Chemokine
22%
Macaca fascicularis
22%
Human Immunodeficiency Virus Antigen
22%
Agonist
22%
Human Immunodeficiency Virus 1
21%
Disease Free Survival
18%
Allele
18%
Cyclophosphamide
16%
Antigen Specificity
16%
Low Drug Dose
16%
CCL27
15%
Lymphocyte
13%
Major Histocompatibility Complex
13%
CD40 Ligand
13%
Neutrophil Granulocyte
11%
Granulocyte Macrophage Colony-Stimulating Factor
10%
Urelumab
9%
Mouse
8%
Effector Cell
7%
CD4
7%
Adjuvant
6%
RNA Sequence
5%
Chemotaxis
5%
Volume
5%
Pharmacology, Toxicology and Pharmaceutical Science
Irinotecan
54%
Metastatic Colorectal Cancer
45%
Guadecitabine
45%
Clinical Trial
26%
Malignant Neoplasm
26%
Overall Survival
25%
Chemotherapy
25%
Regorafenib
22%
Pancreas Tumor
22%
Colorectal Cancer
22%
Ipilimumab
22%
Trametinib
22%
Biological Activity
22%
Mitogen Activated Protein Kinase Kinase Inhibitor
22%
Vasculotropin Receptor
22%
Tumor Vaccine
22%
Solid Malignant Neoplasm
22%
Differentiated Thyroid Cancer
22%
Pancreas Cancer
22%
Pembrolizumab
22%
Protein Tyrosine Kinase
22%
Protein Tyrosine Kinase Inhibitor
22%
Pazopanib
22%
Phase I Trials
22%
Ascorbic Acid
22%
Pancreas Adenocarcinoma
18%
Neoplasm
17%
Progression Free Survival
15%
Fourier Transform Infrared Spectroscopy
15%
Differential Scanning Calorimetry
15%
Adverse Event
12%
Anemia
12%
DNA Methyltransferase
11%
Histone Deacetylase
11%
Urelumab
11%
Tumor Microenvironment
10%
Neutropenia
9%
Folinic Acid
9%
Fluorouracil
9%
Oxaliplatin
9%
Growth Factor
8%
Gene Delivery
7%
Thermal Exposure
7%
Dynamic Light Scattering
7%
Thermostability
7%
Disease
7%
Diarrhea
7%
Azacitidine
5%
Thrombocytopenia
5%
Preclinical Study
5%